Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-03-05 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2021-03-05 English
6-K
Regulatory Filings
2021-03-03 English
Cleansing Notice and Appendix 2A 16 pages 427.2KB
Regulatory Filings Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) related to the issuance of shares by Mesoblast Limited. It includes details about the issuance of fully paid ordinary shares to sophisticated and professional investors under a private placement, references to Appendix 3B filings, and an Appendix 2A application for quotation of securities. The content focuses on regulatory compliance and the application for quotation of new securities on the ASX. There are no financial statements, earnings data, management discussion, or other report content. The document is a regulatory announcement about securities issuance and quotation, not a financial report or detailed investor presentation. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-03-02 English
6-K
Regulatory Filings
2021-03-02 English
Mesoblast Raises US$110M Led By US Strategic Investor Group 3 pages 203.5KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a US$110 million private placement financing led by a strategic US investor group. It details the terms of the financing, use of proceeds, and background information about the company and its products. There are no financial statements, quarterly or annual results, or detailed financial analysis. The document focuses on capital raising activities and financing terms rather than reporting financial performance or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report or a certification.
2021-03-01 English
Proposed issue of Securities - MSB 6 pages 31.0KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a proposed issue of securities by Mesoblast Limited. It details the number and types of securities to be issued, issue price, proposed issue date, and compliance with ASX listing rules. There are no financial statements or detailed financial performance data included. The document is focused on informing about a capital raising event, specifically a placement or other type of securities issue. This fits the definition of a Capital/Financing Update (CAP). The document length is 7642 characters, which is sufficient to be a full announcement rather than a brief notice. Therefore, the appropriate classification is CAP.
2021-03-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.